Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03853616 2026-04-16

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

48 enrolled

Acute Lymphoblastic Leukemia Recurrent

NCT05101213 2026-04-16

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Phase 1 Not yet recruiting

Adenoviridae Infections, Cytomegalovirus Infections, Hematologic Neoplasms

NCT07532746 2026-04-16

A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies

55 enrolled

Recurrence, Hematologic Neoplasms

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04177004 2026-04-15

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Phase 1 Suspended

53 enrolled

Hematologic Neoplasms

NCT04972942 2026-04-15

ALLO-T-DART

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05886049 2026-04-15

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT06823167 2026-04-15

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

117 enrolled

Hematologic Neoplasms

NCT07025564 2026-04-15

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

12 enrolled

Leukemia, Myeloid, Acute

NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

LymphoidMyeloidOther hematologic neoplasm

24 enrolled

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02390752 2026-04-14

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

CNSLymphoidOther hematologic neoplasmSarcoma

54 enrolled

Sarcoma, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03896269 2026-04-14

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

38 enrolled

Leukemia, Myelomonocytic, Chronic

NCT05131022 2026-04-14

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

572 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06034470 2026-04-14

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT07195916 2026-04-14

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

280 enrolled

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07527221 2026-04-14

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Phase 1 Not yet recruiting

40 enrolled

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT01861314 2026-04-13

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

15 enrolled

Leukemia, Myeloid, Acute

NCT02160015 2026-04-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02381886 2026-04-13

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

CNSGastrointestinalMyeloidOther hematologic neoplasm

166 enrolled

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03041688 2026-04-13

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

58 enrolled

Leukemia, Myeloid, Acute

NCT03399799 2026-04-13

MonumenTAL-1

279 enrolled 2 FDA

Hematologic Neoplasms

NCT03816319 2026-04-13

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Classical hematologyMyeloidOther hematologic neoplasm

42 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03816345 2026-04-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

300 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT03983824 2026-04-13

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

48 enrolled

Leukemia, Myeloid, Acute

NCT04190550 2026-04-13

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

24 enrolled

Leukemia, Myeloid, Acute

NCT04301076 2026-04-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05424822 2026-04-13

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

167 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05453903 2026-04-13

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT06047886 2026-04-13

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

50 enrolled

Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

NCT06146257 2026-04-13

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06484062 2026-04-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

54 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06514261 2026-04-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

45 enrolled

Leukemia, Myeloid, Acute

NCT06618001 2026-04-13

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

115 enrolled

Leukemia, Myeloid, Acute

NCT06651229 2026-04-13

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

155 enrolled

Leukemia, Myeloid, Acute

NCT06656494 2026-04-13

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

266 enrolled